208 related articles for article (PubMed ID: 21910729)
61. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
[TBL] [Abstract][Full Text] [Related]
62. α-galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice.
Chen Q; Guo X; Deng N; Liu L; Chen S; Wang A; Li R; Huang Y; Ding X; Yu H; Hu S; Nie H
J Cell Mol Med; 2019 Feb; 23(2):1072-1085. PubMed ID: 30421497
[TBL] [Abstract][Full Text] [Related]
63. Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.
Barthelemy A; Ivanov S; Hassane M; Fontaine J; Heurtault B; Frisch B; Faveeuw C; Paget C; Trottein F
mBio; 2016 Nov; 7(6):. PubMed ID: 27803187
[TBL] [Abstract][Full Text] [Related]
64. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists.
Kulkarni RR; Villanueva AI; Elawadli I; Jayanth P; Read LR; Haeryfar SM; Sharif S
Cell Immunol; 2012; 277(1-2):33-43. PubMed ID: 22795895
[TBL] [Abstract][Full Text] [Related]
65. Synthesis of C6''-modified α-C-GalCer analogues as mouse and human iNKT cell agonists.
Guillaume J; Seki T; Decruy T; Venken K; Elewaut D; Tsuji M; Van Calenbergh S
Org Biomol Chem; 2017 Mar; 15(10):2217-2225. PubMed ID: 28221388
[TBL] [Abstract][Full Text] [Related]
66. Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.
Weinkove R; Brooks CR; Carter JM; Hermans IF; Ronchese F
Haematologica; 2013 Mar; 98(3):376-84. PubMed ID: 23065503
[TBL] [Abstract][Full Text] [Related]
67. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
[TBL] [Abstract][Full Text] [Related]
68. Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.
Braun NA; Mendez-Fernandez YV; Covarrubias R; Porcelli SA; Savage PB; Yagita H; Van Kaer L; Major AS
Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1758-65. PubMed ID: 20539017
[TBL] [Abstract][Full Text] [Related]
69. Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling.
Emoto M; Shimizu T; Koike H; Yoshizawa I; Hurwitz R; Kaufmann SH; Emoto Y
Immunology; 2010 Jan; 129(1):62-74. PubMed ID: 20028429
[TBL] [Abstract][Full Text] [Related]
70. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
71. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
72. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
[TBL] [Abstract][Full Text] [Related]
73. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
74. Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells.
Tashiro T; Sekine-Kondo E; Shigeura T; Nakagawa R; Inoue S; Omori-Miyake M; Chiba T; Hongo N; Fujii S; Shimizu K; Yoshiga Y; Sumida T; Mori K; Watarai H; Taniguchi M
Int Immunol; 2010 Apr; 22(4):319-28. PubMed ID: 20181652
[TBL] [Abstract][Full Text] [Related]
75. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
[TBL] [Abstract][Full Text] [Related]
76. Multiple mechanisms involved in diabetes protection by lipopolysaccharide in non-obese diabetic mice.
Wang J; Cao H; Wang H; Yin G; Du J; Xia F; Lu J; Xiang M
Toxicol Appl Pharmacol; 2015 Jun; 285(3):149-58. PubMed ID: 25896969
[TBL] [Abstract][Full Text] [Related]
77. During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment.
Duthie MS; Kahn SJ
Immunology; 2006 Nov; 119(3):355-61. PubMed ID: 16879622
[TBL] [Abstract][Full Text] [Related]
78. NK T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen.
Laloux V; Beaudoin L; Jeske D; Carnaud C; Lehuen A
J Immunol; 2001 Mar; 166(6):3749-56. PubMed ID: 11238616
[TBL] [Abstract][Full Text] [Related]
79. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
80. Interleukin-13 Pathway Alterations Impair Invariant Natural Killer T-Cell-Mediated Regulation of Effector T Cells in Type 1 Diabetes.
Usero L; Sánchez A; Pizarro E; Xufré C; Martí M; Jaraquemada D; Roura-Mir C
Diabetes; 2016 Aug; 65(8):2356-66. PubMed ID: 27207542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
